Attached files

file filename
10-K - 10-K - Adverum Biotechnologies, Inc.advm-10k_20191231.htm
EX-32.1 - EX-32.1 - Adverum Biotechnologies, Inc.advm-ex321_26.htm
EX-31.2 - EX-31.2 - Adverum Biotechnologies, Inc.advm-ex312_18.htm
EX-31.1 - EX-31.1 - Adverum Biotechnologies, Inc.advm-ex311_10.htm
EX-23.1 - EX-23.1 - Adverum Biotechnologies, Inc.advm-ex231_492.htm
EX-21.1 - EX-21.1 - Adverum Biotechnologies, Inc.advm-ex211_24.htm
EX-10.36 - EX-10.36 - Adverum Biotechnologies, Inc.advm-ex1036_1450.htm
EX-4.3 - EX-4.3 - Adverum Biotechnologies, Inc.advm-ex43_598.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of Adverum Biotechnologies, Inc. for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Thomas Leung, as Chief Financial Officer of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.

 

 

 

 

 

 

 

Date:

March 12, 2020

 

By:

/s/ Thomas Leung

 

 

 

 

Thomas Leung

 

 

 

 

Chief Financial Officer

(Principal Financial and Accounting Officer)